Atyr PHARMA (NASDAQ:ATYR) Earns Outperform Rating from Analysts at Leerink Partners

Leerink Partners assumed coverage on shares of Atyr PHARMA (NASDAQ:ATYR) in a research report sent to investors on Tuesday morning, MarketBeat reports. The brokerage issued an outperform rating and a $16.00 price objective on the stock.

Several other analysts have also commented on ATYR. Cantor Fitzgerald started coverage on shares of Atyr PHARMA in a research report on Monday, January 6th. They set an “overweight” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price target on shares of Atyr PHARMA in a research note on Tuesday, December 10th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Atyr PHARMA currently has an average rating of “Buy” and an average price target of $18.60.

Atyr PHARMA Trading Up 4.4 %

Shares of ATYR opened at $4.44 on Tuesday. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02. The firm has a 50-day moving average price of $3.58 and a 200 day moving average price of $2.86. Atyr PHARMA has a 12-month low of $1.42 and a 12-month high of $4.57. The firm has a market capitalization of $372.27 million, a P/E ratio of -4.72 and a beta of 1.10.

Institutional Trading of Atyr PHARMA

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its stake in shares of Atyr PHARMA by 52.0% in the third quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company’s stock valued at $55,000 after buying an additional 10,754 shares in the last quarter. Alterna Wealth Management Inc. purchased a new position in Atyr PHARMA during the 4th quarter valued at about $36,000. Kingswood Wealth Advisors LLC acquired a new position in Atyr PHARMA in the 4th quarter valued at about $170,000. American Century Companies Inc. purchased a new stake in Atyr PHARMA during the fourth quarter worth about $319,000. Finally, Raymond James Financial Inc. purchased a new stake in Atyr PHARMA during the fourth quarter worth about $39,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.